Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Alexion Pharmaceuticals ( ALXN) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.9%. By the end of trading, Alexion Pharmaceuticals fell $2.47 (-2.6%) to $91.91 on average volume. Throughout the day, 1,406,706 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1,509,700 shares. The stock ranged in price between $91.06-$94.66 after having opened the day at $94.66 as compared to the previous trading day's close of $94.38. Other companies within the Health Care sector that declined today were: Dynavax Technologies Corporation ( DVAX), down 43.3%, Echo Therapeutics ( ECTE), down 25.8%, Aoxing Pharmaceutical Company ( AXN), down 15.4% and Senesco Technologies ( SNTI), down 9.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.1 billion and is part of the drugs industry. The company has a P/E ratio of 63.6, above the S&P 500 P/E ratio of 17.7. Shares are down 0.9% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Cormedix ( CRMD), down 24.3%, Cardium Therapeutics ( CXM), down 18.4%, ACADIA Pharmaceuticals ( ACAD), down 14.8% and OvaScience ( OVAS), down 11.4% , were all gainers within the health care sector with Boston Scientific ( BSX) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk